EGFR and cancer: An earlier seminal study deciphered the evolution and clinical impact of co‐occurring genetic alterations in 1122 EGFR‐mutated NSCLC patients by means of the Guardant 360 ctDNA assay, which covered single‐nucleotide variants, small insertions/deletions (indels), gene rearrangements/fusions, and copy‐number gains across 68 clinically relevant cancer genes [82].